
Retrophin Announces Agreement to Acquire Orphan Technologies
NewsSAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >





Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
NewsSAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. Read the press release >





Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
NewsSAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). Read the press release >


Eric Dube, Ph.D., Speaks at Black Women’s Health Imperative Event
NewsAugust 12, 2020 - the Black Women’s Health Imperative hosted a national webinar with its partner, the National Coalition of 100 Black Women, Inc. entitled “Our Health, Our Community: Mobilizing for the Survival of Black Women,” in partnership with EBONY.


Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100
NewsSAN DIEGO (August 3, 2020) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president and chief executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Read the press release >





Retrophin Reports Second Quarter 2020 Financial Results
NewsSAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its second quarter 2020 financial results and provided a corporate update. Read the press release >


Connecting More People to Optimal Rare Disease Care
News, Stories & InsightsAn update on our partnership with Children's National Rare Disease Institute.


Eric Dube, Ph.D., Interviewed by Rare Revolution
NewsJuly 1, 2020 -- Our CEO and president Eric Dube, Ph.D., recently spoke with Rare Revolution Magazine about motivation, inspiration, challenges and hope.